Cardiovascular, Diabetes & Metabolic Medicines (Antihypertensives, Lipid-Lowering, Antiplatelets, Anticoagulants, Antidiabetics)

At Global Pharma Healthcare, we provide a complete range of cardiovascular and metabolic therapies, covering hypertension, heart failure, lipid disorders, and diabetes management. Our antihypertensive portfolio includes ACE inhibitors such as enalapril, lisinopril, ramipril, captopril and fixed-dose combinations like perindopril with indapamide. - Angiotensin receptor blockers (ARBs) are available as losartan, irbesartan, telmisartan, and combinations with hydrochlorothiazide. - Diuretics include hydrochlorothiazide, spironolactone, torasemide, furosemide, and fixed-dose spironolactone/torasemide options. - Calcium channel blockers include amlodipine, nifedipine, verapamil, as well as combinations such as amlodipine with atenolol or amlodipine with atorvastatin. - Beta blockers offered include atenolol, carvedilol, nebivolol, including nebivolol combinations with hydrochlorothiazide or amlodipine. - For advanced heart failure treatment, we supply sacubitril/valsartan and hydralazine as a vasodilator option. - Lipid lowering treatments include rosuvastatin, atorvastatin, simvastatin, fenofibrate, ezetimibe, and bempedoic acid. - Antiplatelet and anticoagulant options include aspirin, clopidogrel, apixaban, and related agents. Within diabetes care, we provide metformin, glimepiride, gliclazide, glipizide, glibenclamide, repaglinide, pioglitazone, as well as modern oral therapies including sitagliptin, vildagliptin, linagliptin, empagliflozin, dapagliflozin, acarbose and multiple fixed-dose combinations such as vildagliptin with metformin, sitagliptin with metformin, empagliflozin with metformin, dapagliflozin with metformin, and triple therapy combinations like empagliflozin with linagliptin and metformin. This broad portfolio ensures comprehensive coverage across Type 2 diabetes management, with some of the newest molecules in diabetes treatments.